Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Atezolizumab + Carboplatin + Nab-paclitaxel |
Indication/Tumor Type | lung large cell carcinoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | lung large cell carcinoma | sensitive | Atezolizumab + Carboplatin + Nab-paclitaxel | Guideline | Actionable | Combination Paraplatin (carboplatin), Abraxane (nab-paclitaxel), and Tecetriq (atezolizumab) is in guidelines as first-line therapy for patients with large cell lung cancer with CD274 (PD-L1) expression of greater than or equal to 1%, and negative status for EGFR, ALK, ROS1, BRAF, RET, and MET exon 14 skipping mutations (NCCN.org). | detail... |
PubMed Id | Reference Title | Details |
---|---|---|
NCCN.org | Full reference... |